Collaboration announced for analysis of compound combination experiments
As combination therapies have gained importance, compound combination experiments have become increasingly common in drug discovery and development. Under the new collaboration between Genedata (Basel, Switzerland) and AstraZeneca (London, UK), scientists will use Genedata Screener® as a data analysis platform for the large volumes of data produced by these experiments.
Eric Tang, associate principle scientist at AstraZeneca explained, “Typically, compound combination experiments compare 50 or more compounds across a number of cell lines in a single study, resulting in the analysis of hundreds of 384/1536 well plates. Genedata Screener can handle these large datasets and enable us to generate and compare results for the same compound combinations in different cell lines, and review alternative analysis for the same data sets.”
He continued, “Moreover, Screener helps standardize data analysis giving us more quality time to conduct detailed analysis.”
The technology has the ability to process data in under 30 minutes, eliminating time-consuming manual analysis. Among other characteristics designed to address challenges related to large datasets, the Genedata Screener also allows researchers to interactively inspect raw data and check the quality of normalized values.
Othmar Pfannes, Chief Executive Officer of Genedata, hopes the collaboration with AstraZeneca will help to advance Genedata Screener as the platform of choice for the analysis of compound combination experiments.
